Implant Sciences (OTCQB:IMSC) Wednesday announced that it has been issued a US patent which covers a method for removing particles from a target surface to increase sample collection.
The company, which supplies detection systems for homeland security and defense markets, said it was issued patent number 8,122,756 "Narcotics and Explosives Particle Removal System" from the US Patent and Trademark Office.
"Non-contact sample collection enables a wider range of deployment options for trace detection technologies. This invention is
aimed at improving the collection efficiency of our non-contact sampling technologies," Implant Sciences' vice president of
technology Todd Silvestri said.
Implant's president and chief executive Glenn D. Bolduc added: "This latest patent, the twelfth we have received, reaffirms Implant Sciences' commitment to being a true innovator in explosives and narcotics trace detection.
"New technologies that we have introduced include non-radioactive ionization, non-contact sampling, and automatic self-calibration.
The breakthroughs made by our technology group continue to open new market opportunities for the Company and build shareholder value," Bolduc said.
Implant has developed proprietary technologies used in its explosive and drugs detection systems which ship to a growing number of locations domestically and internationally.
The company's QS-H150 portable explosives trace detector has received a Qualified Anti-Terrorism Technology Designation and the company's QS-B220 bench-top explosives and narcotics trace detector has received a Developmental Testing & Evaluation Designation by the US Department of Homeland Security.
Earlier this week, the company named Bill McGann as chief operating officer and as a member of the board of directors.
As a pioneer in the explosive trace detection industry, McGann co-founded Ion Track instruments, the first explosive trace
detection provider to get certification from the US Transportation Security Administration.
With over 70 research proposals to his name, McGann has authored 20 scientific publications and over 25 patents in the nuclear, chemical and biological detection technologies.
In recent months the company has signed contracts to supply its detection equipment to clients in Africa, the Middle East, China and Japan.